Newly-issued UK advice to medicines suppliers on preparing for the end of its Brexit transition period with the EU, currently set for 31 December, has received a mixed response from the UK and European off-patent industry.
Industry Offers Mixed Response To Latest Brexit Advice
Letter From UK’s DHSC Warns Of Disruption And Advises Stockpiling
While the off-patent industry has welcomed concrete advice from the UK government over potential disruptions to medicines supplies when the country’s transition period with the EU expires on 31 December, concerns have been raised over the ability to build up safety stocks in the context of the COVID-19 pandemic, as well as a lack of clarity over the future regulatory landscape and pandemic-related procurement initiatives.
